Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Perampanel (Fycompa - Eisai Ltd.) indication: epilepsy, partial-onset seizures. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC final recommendation. 2013 Authors' conclusions The Canadian Drug Expert Committee (CDEC) recommends that perampanel be listed as an adjunctive therapy in the management of partial-onset seizures in patients with epilepsy who are not satisfactorily controlled with conventional therapy, if the following clinical criteria and condition are met:
1.Patients are currently receiving two or more antiepileptic drugs (AEDs).
2. Less costly AEDs are ineffective or not appropriate. Indexing Status Subject indexing assigned by CRD MeSH Epilepsy; Humans; Pyridones Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32014000877 Date abstract record published 17/07/2014 |